PCS-499

DB15122InvestigationalSmall molecule

PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).

Formula / weight: C₁₃H₂₀N₄O₃ · 285.359 g/mol (avg)
Code names: CTP-499 · PCS-499

Resolves to

Compound

UNIIFLV771E8ZVCAS1268605-91-9ChEMBLCHEMBL4297371

Structure

InChIKeyNSMXQKNUPPXBRG-WHPHVCHMSA-NSMILES[2H]C([2H])([2H])[C@H](O)C([2H])([2H])CCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O

What you can answer from here — as of October 30, 2025

370Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of PCS-499, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account